1. aBeadle, C. D.; Coates, D. A.; Hao, J.; Krushinski, J. H., Jr.; Reinhard, M. R.; Schaus, J. M.; Wolfangel, C. D. 3,4-Dihydroisoquinolin-2(1H)-yl Compounds. WO 2014193781 A1, 2014.
2. bStephenson, G. A Crystalline Form of 2-(2,6-Dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone for the Treatment of Parkinson’s Disease. WO 2017070068 A1, 2017.
3. Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor
4. A Study
of LY3154207 in
Participants with Dementia Due to Lewy Body Dementia (LBD) Associated
with Idiopathic Parkinson’s Disease (PD) or Dementia with Lewy
Bodies (DLB) (PRESENCE). ClincalTrials.gov (U.S. National
Institutes of Health, Bethesda, MD), October 10, 2017. https://clinicaltrials.gov/ct2/show/NCT03305809?intr=LY3154207 (accessed 2020-01-18).